Novel Approach for Evaluating the Effectiveness of Biological Drugs in Patients with Plaque Psoriasis: Real-World Experience of a Single-Centre Study in Poland.

Introduction: Biologic therapies have revolutionized psoriasis treatment, offering targeted interventions that significantly improve outcomes for patients with moderate to severe forms of the disease. In Poland, biologic treatment for psoriasis is funded through the National Health Service's B.47 program, available since 2013. Aim: This study aimed to perform a retrospective analysis of the effectiveness of biologic treatments during the first year of therapy in patients with plaque psoriasis, treated with biologic agents under the B.47 program at a single center in Poland. Methods: Medical records of patients with plaque psoriasis who were enrolled in the National Health Service's B.47 drug program at the dermatology department between January 1, 2013, and August 2, 2024, were reviewed. This retrospective chart review utilized secondary data from these records. Ultimately, 159 patients totaling 300 drug-periods were enrolled to the study. Results: Six distinct patterns of treatment response emerged within the first year. Anti-IL-17AF therapy achieved complete remission (PASI-100) in the shortest time (53.8 days vs 101.7 days for a total population, Conclusion: The study highlights the critical importance of strategic selection of the treatment to optimize long-term outcomes.